Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Certolizumab Pegol in Chronic Plaque Psoriasis
NCT00245765Phase 2Completed
- Sponsor
- UCB
- Start
- Oct 2005
- Primary completion
- Nov 2006
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of certolizumab pegol in psoriasis (3 arms), sponsored by UCB. Primary endpoints: Psoriasis Activity and Severity Index 75 Response at 12 weeks and Physician's Global Assessment of Clear or Almost Clear at 12 weeks. Started Oct 2005; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT00245765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00245765.